NMT1 and neoplasm: Concurrently, the NMT1 inhibitor PCLX-001, at a concentration of 0.1 μmol/L, reduces PD-L1 membrane localization on tumor cells by inhibiting CHP1 myristoylation, decreasing PD-L1 availability to interact with PD-1 on T cells [44].